Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

providing a new first-line biologic treatment option for patients and has been shown as superior to Stelara and Enbrel in trials. Currently, all biologic treatments for psoriasis, including anti ...

In the Phase III ICONIC-LEAD trial, 75% of adolescents with moderate-to-severe plaque psoriasis treated with icotrokinra ...

As Fierce Pharma points out, patent expirations are a routine occurrence in the pharmaceutical world, but 2025 stands out for the unusually large number of drugs affected. Among the companies facing ...

The specter of tariffs is likely to overshadow what was a positive quarter for J&J. The company’s adjusted earnings rose 2.2% ...

By Patrick Wingrove and Bhanvi Satija (Reuters) -Johnson & Johnson on Tuesday reported first-quarter revenue and profit above ...

STEQEYMA is available in both subcutaneous injection and intravenous infusion and is indicated for the treatment of plaque psoriasis (PsO ... given the fact that Stelara ranks as one of the ...

Johnson & Johnson has reported a strong first-quarter performance, surpassing Wall Street expectations and showcasing the power of its oncology portfolio. The company's revenue and profit both ...

STEQEYMA is available in both subcutaneous injection and intravenous infusion and is indicated for the treatment of plaque psoriasis (PsO ... given the fact that Stelara ranks as one of the most ...